Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Sudan: Conflict, cancer care, and ripple effects on the region

Dr Nazik Hammad - University of Toronto, Toronto, Canada

Sudan: Conflict, cancer care, and ripple effects on the region ( Dr Nazik Hammad - University of Toronto, Toronto, Canada )

Geriatric oncology in resource-limited settings

Dr Enrique Soto Perez de Celis - National Institute of Medical Sciences, Mexico...

Geriatric oncology in resource-limited settings ( Dr Enrique Soto Perez de Celis - National Institute of Medical Sciences, Mexico City, Mexico )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

Hormonal Therapy and Complications

Dr Gerardo Barrantes - Hospital Mexico, Costa Rica

Hormonal Therapy and Complications ( Dr Gerardo Barrantes - Hospital Mexico, Costa Rica )

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows...

Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy ( Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA )

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

ASCO 2023: Latest in PARP inhibitors in prostate cancer

Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg

ASCO 2023: Latest in PARP inhibitors in prostate cancer ( Prof Rana McKay, Dr Friederike Schlurmann, Prof Gunhild von Amsberg )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

More from ecancer